217 related articles for article (PubMed ID: 32863894)
21. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
22. Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.
Miao Y; Zhu S; Li H; Zou J; Zhu Q; Lv T; Song Y
J Thorac Dis; 2017 Oct; 9(10):3927-3937. PubMed ID: 29268403
[TBL] [Abstract][Full Text] [Related]
23. Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.
Honguero Martínez AF; García Jiménez MD; García Vicente A; López-Torres Hidalgo J; Colon MJ; van Gómez López O; Soriano Castrejón ÁM; León Atance P
Rev Esp Med Nucl Imagen Mol; 2016; 35(3):159-64. PubMed ID: 26514322
[TBL] [Abstract][Full Text] [Related]
24. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
25. Performance of
Zhang M; Bao Y; Rui W; Shangguan C; Liu J; Xu J; Lin X; Zhang M; Huang X; Zhou Y; Qu Q; Meng H; Qian D; Li B
Front Oncol; 2020; 10():568857. PubMed ID: 33134170
[TBL] [Abstract][Full Text] [Related]
26. Association between cigarette smoking history, metabolic phenotypes, and
Zhang X; Guo X; Gao Q; Zhang J; Zheng J; Zhao G; Okuda K; Tartarone A; Jiang M
J Thorac Dis; 2023 Oct; 15(10):5689-5699. PubMed ID: 37969305
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.
Kus T; Aktas G; Sevinc A; Kalender ME; Yilmaz M; Kul S; Oztuzcu S; Oktay C; Camci C
Onco Targets Ther; 2015; 8():3749-56. PubMed ID: 26719702
[TBL] [Abstract][Full Text] [Related]
28. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
[TBL] [Abstract][Full Text] [Related]
29. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
30. Association between histopathological subtype,
Qiang G; Huang W; Liang C; Xu R; Yan J; Xu Y; Wang YE; DA J; Shi B; Guo Y; Liu D
Oncol Lett; 2016 Mar; 11(3):1769-1777. PubMed ID: 26998075
[TBL] [Abstract][Full Text] [Related]
31. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer.
Choi YJ; Kim MJ; Lee BH; Kwon MJ; Hwang HS
Yonsei Med J; 2016 Jan; 57(1):232-7. PubMed ID: 26632406
[TBL] [Abstract][Full Text] [Related]
32. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
[TBL] [Abstract][Full Text] [Related]
33. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
[TBL] [Abstract][Full Text] [Related]
34. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
35. Improving diagnostic performance of
Yang DD; Mirvis E; Goldring J; Patel ARC; Wagner T
Clin Radiol; 2019 Oct; 74(10):818.e17-818.e23. PubMed ID: 31420186
[TBL] [Abstract][Full Text] [Related]
36. Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis.
Yao G; Zhou Y; Gu Y; Wang Z; Yang M; Sun J; Luo Q; Zhao H
J Cancer; 2020; 11(18):5511-5517. PubMed ID: 32742498
[No Abstract] [Full Text] [Related]
37. Predicting EGFR mutation subtypes in lung adenocarcinoma using
Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
[TBL] [Abstract][Full Text] [Related]
38. Correlations Study Between
Yang B; Wang QG; Lu M; Ge Y; Zheng YJ; Zhu H; Lu G
Front Oncol; 2019; 9():589. PubMed ID: 31380265
[No Abstract] [Full Text] [Related]
39. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS
Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227
[TBL] [Abstract][Full Text] [Related]
40. Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation.
Lv YL; Liu HB; Yuan DM; Zhou L; Jin SX; Song Y
Transl Cancer Res; 2019 Aug; 8(4):1027-1034. PubMed ID: 35116846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
